Dogwood Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

Accrued Expenses

9 Months Ended

Sep. 30, 2022

Accrued Expenses

Accrued Expenses

5Accrued Expenses

Accrued expenses consist of the following:


		September 30,			December 31,
		2022			2021
Accrued compensation		$	261,347		$	532,678
Accrued interest on preferred members’ interests			188,085			188,085
Accrued clinical research costs			379,721			138,522
Accrued director fees			15,500			31,000
Accrued professional fees			103,575			24,100
Other miscellaneous accrued expenses			5,498			7,375
		$	953,726		$	921,760